RxDoctor Payments Data

Guadalupe Telford

Adult Health · Las Cruces, NMNPI 1063693281

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $706 and has fallen 94.4% since, to $40 in 2025.

$1,678in general payments, 2019–2025

Across 64 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$224
  • Bayer$182
  • Mayne Pharma Commercial LLC$167
  • Sumitomo Pharma America, Inc.$158
  • Pfizer$151
  • Abbott$133
  • plus $663 from 14 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 80th percentile of 52 adult health providers in New Mexico.

See all adult health providers in New Mexico

Medicare billing

Part B allowed, 2024
$12,333
Medicare patients
87
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol94$6,415
PremarinEstrogens, Conjugated14$6,316
VienvaLevonorgestrel/Ethin.Estradiol20$269
Fluconazole15$137
Triamcinolone Acetonide25$113
Medroxyprogesterone Acetate12$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$151$6,31614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 adult health providers in New Mexico.

Other adult health in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →